UPS: Opportunities and challenges for gastric cancer treatment

Gastric cancer remains the fourth most frequently diagnosed malignancy and the fifth leading cause of cancer-related mortality worldwide owning to the lack of efficient drugs and targets for therapy. Accumulating evidence indicates that UPS, which consists of E1, E2, and E3 enzymes and proteasome, p...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2023-04, Vol.13, p.1140452-1140452
Main Authors: Yang, Hang, Ai, Huihan, Zhang, Jialin, Ma, Jie, Liu, Kangdong, Li, Zhi
Format: Article
Language:English
Subjects:
E3 ligase
gastric cancer
Oncology
PROTAC
therapy
UPS modulator
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gastric cancer remains the fourth most frequently diagnosed malignancy and the fifth leading cause of cancer-related mortality worldwide owning to the lack of efficient drugs and targets for therapy. Accumulating evidence indicates that UPS, which consists of E1, E2, and E3 enzymes and proteasome, plays an important role in the GC tumorigenesis. The imbalance of UPS impairs the protein homeostasis network during development of GC. Therefore, modulating these enzymes and proteasome may be a promising strategy for GC target therapy. Besides, PROTAC, a strategy using UPS to degrade the target protein, is an emerging tool for drug development. Thus far, more and more PROTAC drugs enter clinical trials for cancer therapy. Here, we will analyze the abnormal expression enzymes in UPS and summarize the E3 enzymes which can be developed in PROTAC so that it can contribute to the development of UPS modulator and PROTAC technology for GC therapy.
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2023.1140452